康基医疗 (09997.HK) 悉数行使超额配股权 额外筹 4.55 亿港元

格隆汇 · 2020-06-30

格隆汇 6 月 30 日丨康基医疗 (09997.HK) 宣布,联席全球协调人 (代表国际包销商) 已于2020年6月30日悉数行使招股说明书所述的超额配股权,涉及合共 3380.95 万股股份,占全球发售项下初步可供认购发售股份 (行使任何超额配股权前) 的约 15%,以补足全球发售中的超额分配。售股股东将以每股待售股份 13.88 港元 (不包括 0.0027% 证监会交易徵费及 0.005% 联交所交易费)(即全球发售项下每股发售股份的发售价) 销售待售股份。

因超额配股权获悉数行使,售股股东将自出售待售股份收取的所得款项净额约为 4.547 亿港元 (经扣除售股股东按比例应付的包销佣金及手续费)。公司将不会就出售待售股份收取任何所得款项。

Long Bridge Securities Ltd is a New Zealand registered Financial Service Provider (FSP number: FSP600050), and is a member of the Financial Dispute Resolution Scheme, a New Zealand independent dispute resolution service provider.

All data and contents of the Long Bridge website (longbridge.global) are for investors' reference only. Before conducting investment activities, investors should fully understand the relevant products, clearly know their potential risks, and make rational decisions based on their own risk tolerance; and investors should be aware that all investment activities involve risks and investment activities may not be suitable for every investor.

Customer Service Hotline:400-071-2688

0800 33 9033 / (09) 533 9033(New Zealand)

Support Email: service@longbridge.global
简体中文